PFE.BA - Pfizer Inc.

Buenos Aires - Buenos Aires Delayed Price. Currency in ARS
371.40
0.00 (0.00%)
At close: 11:47AM ART
Stock chart is not supported by your current browser
Previous Close371.40
Open371.40
Bid369.45 x 0
Ask550.00 x 0
Day's Range371.40 - 371.40
52 Week Range258.50 - 380.00
Volume700
Avg. Volume676
Market Cap4.388T
Beta0.89
PE Ratio (TTM)105.60
EPS (TTM)3.52
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2015-02-04
1y Target EstN/A
  • Don't Get Greedy With Novavax, Inc. Stock
    Motley Fool10 hours ago

    Don't Get Greedy With Novavax, Inc. Stock

    Novavax's abysmal track record should be a huge red flag for potential shareholders.

  • Eli Lilly’s 1Q18 Estimates: Revenue Growth Expected
    Market Realist11 hours ago

    Eli Lilly’s 1Q18 Estimates: Revenue Growth Expected

    Wall Street analysts expect an ~3.0% increase in Eli Lilly & Co.’s (LLY) 1Q18 revenues to $5.5 billion. Eli Lilly’s products are sold in more than 120 countries, and its international sales comprise ~45.0% of its total revenues. As a result, the company is exposed to currency risk, and foreign exchange is expected to have a positive impact on its overall revenues during 1Q18.

  • Analysts’ Estimates for Eli Lilly & Co.’s 1Q18 Earnings
    Market Realist13 hours ago

    Analysts’ Estimates for Eli Lilly & Co.’s 1Q18 Earnings

    Eli Lilly & Co. (LLY) is a leading US-based pharmaceutical company with a product portfolio covering human health products and animal health products. Eli Lilly is set to release its 1Q18 earnings on April 24.

  • Q1 Earnings Surprise Well in Cards: Healthcare ETFs to Buy
    Zacks13 hours ago

    Q1 Earnings Surprise Well in Cards: Healthcare ETFs to Buy

    Let's dig into the earnings picture of the companies that would drive the performance of the popular health care ETFs in the coming days.

  • Is a Beat in Store for Bristol-Myers (BMY) in Q1 Earnings?
    Zacks14 hours ago

    Is a Beat in Store for Bristol-Myers (BMY) in Q1 Earnings?

    Bristol-Myers (BMY) is scheduled to report Q1 earnings on Apr 26.

  • Why GlaxoSmithKline’s 1Q18 Revenues Are Expected to Fall
    Market Realist15 hours ago

    Why GlaxoSmithKline’s 1Q18 Revenues Are Expected to Fall

    As discussed in the previous article, analysts expect a 2.2% decrease in GlaxoSmithKline’s (GSK) 1Q18 revenues to 7.2 billion pounds due to the impact of divestitures, the negative impact of foreign exchange, and lower sales of some products.

  • Reuters16 hours ago

    FDA declines to approve Pfizer biosimilar of Roche's cancer drug

    Pfizer Inc said on Monday U.S. regulators declined to approve the company's biosimilar of Roche's blockbuster treatment for breast cancer, Herceptin, and sought additional technical information. Herceptin and other complex medicines called biologics are made from living cells, making them difficult to copy with precision.

  • Merck’s Relebactam Met Primary Endpoints in Phase 3 Study
    Market Realist16 hours ago

    Merck’s Relebactam Met Primary Endpoints in Phase 3 Study

    Merck’s (MRK) Relebactam is an investigational beta-lactamase inhibitor for the treatment of certain forms of imipenem-non-susceptible bacterial infections.

  • What Analysts Predict for GlaxoSmithKline’s 1Q18 Earnings
    Market Realist16 hours ago

    What Analysts Predict for GlaxoSmithKline’s 1Q18 Earnings

    GlaxoSmithKline (GSK) is set to release its 1Q18 earnings on April 25, 2018. The below chart shows the company’s revenues and earnings per share (or EPS) since 1Q17 and analysts’ estimates for 1Q18. Analysts estimate the company will post EPS of 24.21 pence on revenues of 7.2 billion pounds in 1Q18.

  • Business Wire16 hours ago

    Pfizer Granted FDA Breakthrough Therapy Designation for TRUMENBA® (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Children Ages 1 to 9 Years

    Pfizer Inc. (NYSE: PFE) today announced that TRUMENBA® (Meningococcal Group B Vaccine) received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for active immunization to prevent invasive disease caused by Neisseria meningitidis group B (MenB) in children ages 1 through 9 years. This is the first Breakthrough Therapy designation for a MenB vaccine to help protect children as young as 1 year of age.

  • MarketWatch16 hours ago

    Pfizer says FDA failed to approve Herceptin biosimilar

    Pfizer Inc. said early Monday that the Food and Drug Administration failed to approve its trastuzumab biosimilar, intended as a lower-cost version of Roche's cancer drug Herceptin. The FDA asked for more ...

  • Business Wire17 hours ago

    Pfizer Provides Update on Proposed Trastuzumab Biosimilar

    Pfizer Inc. (PFE) today announced that it received a Complete Response Letter (CRL) from the United States Food and Drug Administration (FDA) in response to the Biologics License Application for the company’s proposed trastuzumab biosimilar. In the CRL, the FDA highlighted the need for additional technical information. The additional requested information does not relate to safety or clinical data submitted in the application.

  • Business Wire17 hours ago

    MYLOTARG™ Approved In The EU For The Treatment Of Previously Untreated, De Novo, CD33-positive Acute Myeloid Leukemia In Combination With Chemotherapy

    Pfizer Inc. today announced that the European Commission has approved MYLOTARG™ in combination with daunorubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo, CD33-positive acute myeloid leukemia , except acute promyelocytic leukemia .

  • Moody'syesterday

    NMC Health plc -- Moody's assigns first-time Ba1 ratings to NMC Health; outlook stable

    Moody's Investors Service, ("Moody's") has assigned a Ba1 corporate family rating (CFR) and Ba1-PD probability of default rating to NMC Health plc (NMC), the largest healthcare provider in the ...

  • Better Buy: Gilead Sciences, Inc. (GILD) vs. Pfizer (PFE)
    Motley Fool2 days ago

    Better Buy: Gilead Sciences, Inc. (GILD) vs. Pfizer (PFE)

    Which stock wins in a match-up between these huge drugmakers?

  • Analysts’ Ratings for Sarepta Therapeutics and Peers in April
    Market Realist3 days ago

    Analysts’ Ratings for Sarepta Therapeutics and Peers in April

    How Is Sarepta Therapeutics Positioned in 2018? Sarepta Therapeutics (SRPT) is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics, gene therapy, and other genetic approaches for treating rare neuromuscular diseases. Of the 19 analysts covering Sarepta Therapeutics in April 2018, six analysts gave the stock a “strong buy” rating, 11 analysts gave it a “buy” rating, and two analysts gave it a “hold” rating.

  • P&G's vitamin boost could signal more to come
    Reuters4 days ago

    P&G's vitamin boost could signal more to come

    LONDON/CHICAGO (Reuters) - Procter & Gamble's $4.2 billion deal for Merck's vitamin and supplements business demonstrates that major consumer companies remain hungry for health-related products. The fragmented nature of the sector and its appeal to younger consumers makes further M&A activity a likely prospect even after a spate of recent acquisitions. The U.S.-based maker of Tide detergent and Gillette razors announced its plan on Thursday to buy Merck brands such as Seven Seas vitamins.

  • J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit?
    Zacks4 days ago

    J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit?

    Johnson & Johnson (JNJ) and Novartis reported strong first-quarter 2018 earnings results earlier this week.

  • TheStreet.com4 days ago

    Fate of Pfizer Unit in Spotlight After Merck Sells Consumer Business

    Procter & Gamble, which is buying the Merck unit, was previously reported to be in talks to acquire Pfizer's consumer healthcare business.

  • P&G's vitamin boost could signal more to come
    Reuters4 days ago

    P&G's vitamin boost could signal more to come

    LONDON/CHICAGO (Reuters) - Procter & Gamble's $4.2 billion deal for Merck's vitamin and supplements business is the latest example of a major consumer company stocking up on health-related products. Just last month, cleaning product maker Clorox Co agreed to buy multivitamin company Nutranext for $700 million. The moves show how global consumer goods companies are looking to new, interesting areas to offset flagging growth in their core businesses.

  • Business Wire4 days ago

    Pfizer Invites Public to Listen to Webcast of April 26 Annual Meeting of Shareholders

    Pfizer Inc. invites investors and the general public to listen to a webcast of the Annual Meeting of Shareholders at 9:00 a.m. (Eastern Daylight Time) on Thursday, April 26, 2018. To pre-register and access the live audio webcast, visit https://investors.pfizer.com/proxy and click on the “Annual Meeting Webcast” button. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.

  • FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC
    Zacks5 days ago

    FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC

    AstraZeneca (AZN) wins the FDA approval for the label expansion of its marketed drug, Tagrisso, for first-line treatment of adult patients with locally-advanced or metastatic NSCLC.

  • Vyxeos Could Be Jazz Pharmaceuticals’ Long-Term Growth Driver
    Market Realist5 days ago

    Vyxeos Could Be Jazz Pharmaceuticals’ Long-Term Growth Driver

    In 4Q17, Jazz Pharmaceuticals’ (JAZZ) Vyxeos (daunorubicin and cytarabine) generated revenues of $24 million compared to $10 million in 3Q17. In fiscal 2017, Vyxeos reported net revenues of $34 million.

  • How Analysts View Tetraphase Pharmaceuticals in April 2018
    Market Realist5 days ago

    How Analysts View Tetraphase Pharmaceuticals in April 2018

    Tetraphase Pharmaceuticals (TTPH) is a clinical-stage biopharmaceutical company focused on creating novel antibiotics. These antibiotics treat serious and life-threatening multidrug-resistant infections by using the company’s proprietary chemistry technology. Its lead product candidate is eravacycline, which is being developed as an intravenous antibiotic.

  • A Look at the Financial Performance of Spark Therapeutics
    Market Realist6 days ago

    A Look at the Financial Performance of Spark Therapeutics

    Spark Therapeutics (ONCE) generated revenue of $12 million in 2017 compared to $20.1 million in 2016. Under this collaboration, Spark Therapeutics maintains the responsibility for developing SPK-FIX candidates through Phase 1 and 2 trials. In November 2017, this agreement was amended, and Spark received a $10 million up-front payment and was eligible to receive an additional $15 million.